Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
SNY's Cash to Debt is ranked higher than
94% of the 909 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. SNY: No Debt )
SNY' s 10-Year Cash to Debt Range
Min: 0.14   Max: No Debt
Current: No Debt

Interest Coverage 8.34
SNY's Interest Coverage is ranked higher than
56% of the 550 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 120.76 vs. SNY: 8.34 )
SNY' s 10-Year Interest Coverage Range
Min: 7.88   Max: 19.65
Current: 8.34

7.88
19.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 17.28
SNY's Operating margin (%) is ranked higher than
86% of the 860 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.67 vs. SNY: 17.28 )
SNY' s 10-Year Operating margin (%) Range
Min: 15.25   Max: 38.21
Current: 17.28

15.25
38.21
Net-margin (%) 12.27
SNY's Net-margin (%) is ranked higher than
84% of the 860 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.48 vs. SNY: 12.27 )
SNY' s 10-Year Net-margin (%) Range
Min: 7.92   Max: 25.8
Current: 12.27

7.92
25.8
ROE (%) 14.97
SNY's ROE (%) is ranked higher than
89% of the 879 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.98 vs. SNY: 14.97 )
SNY' s 10-Year ROE (%) Range
Min: 5.18   Max: 33.55
Current: 14.97

5.18
33.55
ROA (%) 8.68
SNY's ROA (%) is ranked higher than
88% of the 913 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.21 vs. SNY: 8.68 )
SNY' s 10-Year ROA (%) Range
Min: 2.62   Max: 21.59
Current: 8.68

2.62
21.59
ROC (Joel Greenblatt) (%) 69.54
SNY's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 907 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.70 vs. SNY: 69.54 )
SNY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 31.28   Max: 145.55
Current: 69.54

31.28
145.55
Revenue Growth (%) -1.50
SNY's Revenue Growth (%) is ranked higher than
61% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. SNY: -1.50 )
SNY' s 10-Year Revenue Growth (%) Range
Min: -1.5   Max: 27.4
Current: -1.5

-1.5
27.4
EBITDA Growth (%) -3.70
SNY's EBITDA Growth (%) is ranked higher than
64% of the 702 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.30 vs. SNY: -3.70 )
SNY' s 10-Year EBITDA Growth (%) Range
Min: -3.7   Max: 35.7
Current: -3.7

-3.7
35.7
EPS Growth (%) -12.80
SNY's EPS Growth (%) is ranked higher than
64% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. SNY: -12.80 )
SNY' s 10-Year EPS Growth (%) Range
Min: -12.8   Max: 41.2
Current: -12.8

-12.8
41.2
» SNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

SNY Guru Trades in Q4 2013

Sarah Ketterer 431,317 sh (+277.96%)
HOTCHKIS & WILEY 5,912,375 sh (+23.53%)
Charles Brandes 2,013,300 sh (+18.29%)
Third Avenue Management 16,105 sh (+16.45%)
NWQ Managers 5,832,760 sh (+7.52%)
James Barrow 22,645,140 sh (+5.49%)
Jean-Marie Eveillard 654,462 sh (+0.12%)
Francis Chou 410,000 sh (unchged)
Murray Stahl 26,000 sh (unchged)
John Hussman 22,100 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Ken Fisher 12,818,390 sh (-0.07%)
PRIMECAP Management 2,281,231 sh (-0.12%)
Dodge & Cox 43,628,729 sh (-0.77%)
Manning & Napier Advisors, Inc 312,008 sh (-3.5%)
Mario Gabelli 4,500 sh (-24.37%)
» More
Q1 2014

SNY Guru Trades in Q1 2014

Steven Cohen 300,000 sh (New)
Scott Black 247,100 sh (New)
Bill Nygren 2,600,000 sh (New)
John Buckingham 20,080 sh (New)
Manning & Napier Advisors, Inc 2,923,087 sh (+836.86%)
HOTCHKIS & WILEY 9,804,594 sh (+65.83%)
James Barrow 27,790,116 sh (+22.72%)
Sarah Ketterer 506,901 sh (+17.52%)
PRIMECAP Management 2,476,856 sh (+8.58%)
Charles Brandes 2,072,790 sh (+2.95%)
Ken Fisher 12,926,402 sh (+0.84%)
Dodge & Cox 43,664,887 sh (+0.08%)
Warren Buffett 3,905,875 sh (unchged)
John Hussman 22,100 sh (unchged)
Murray Stahl 26,000 sh (unchged)
Francis Chou 410,000 sh (unchged)
Mario Gabelli 4,500 sh (unchged)
Third Avenue Management 15,706 sh (-2.48%)
NWQ Managers 5,460,055 sh (-6.39%)
Jean-Marie Eveillard 610,749 sh (-6.68%)
» More
Q2 2014

SNY Guru Trades in Q2 2014

Bill Nygren 4,950,000 sh (+90.38%)
PRIMECAP Management 3,011,646 sh (+21.59%)
Sarah Ketterer 567,921 sh (+12.04%)
Charles Brandes 2,182,305 sh (+5.28%)
James Barrow 28,526,802 sh (+2.65%)
John Buckingham 20,344 sh (+1.31%)
Manning & Napier Advisors, Inc 2,961,185 sh (+1.3%)
Ken Fisher 13,079,575 sh (+1.18%)
Warren Buffett 3,905,875 sh (unchged)
Francis Chou 410,000 sh (unchged)
Murray Stahl 26,000 sh (unchged)
Mario Gabelli 4,500 sh (unchged)
John Hussman Sold Out
Dodge & Cox 43,549,909 sh (-0.26%)
HOTCHKIS & WILEY 9,772,061 sh (-0.33%)
Jean-Marie Eveillard 608,568 sh (-0.36%)
Third Avenue Management 13,402 sh (-14.67%)
Scott Black 178,985 sh (-27.57%)
NWQ Managers 2,602,503 sh (-52.34%)
» More
Q3 2014

SNY Guru Trades in Q3 2014

Manning & Napier Advisors, Inc 5,024,798 sh (+69.69%)
PRIMECAP Management 3,891,356 sh (+29.21%)
Bill Nygren 5,670,000 sh (+14.55%)
Sarah Ketterer 593,929 sh (+4.58%)
Charles Brandes 2,248,902 sh (+3.05%)
Mario Gabelli 4,580 sh (+1.78%)
John Buckingham 20,665 sh (+1.58%)
HOTCHKIS & WILEY 9,895,521 sh (+1.26%)
Ken Fisher 13,145,647 sh (+0.51%)
Francis Chou 410,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Murray Stahl 26,000 sh (unchged)
Scott Black 178,410 sh (-0.32%)
Dodge & Cox 43,267,004 sh (-0.65%)
James Barrow 28,293,723 sh (-0.82%)
NWQ Managers 2,409,040 sh (-7.43%)
Third Avenue Management 12,306 sh (-8.18%)
Jean-Marie Eveillard 34,157 sh (-94.39%)
» More
» Details

Insider Trades

Latest Guru Trades with SNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Bill Nygren 2014-09-30 Add 14.55%0.27%$50.89 - $57.29 $ 46.81-13%5670000
Jean-Marie Eveillard 2014-09-30 Reduce -94.39%0.07%$50.89 - $57.29 $ 46.81-13%34157
PRIMECAP Management 2014-09-30 Add 29.21%0.05%$50.89 - $57.29 $ 46.81-13%3891356
NWQ Managers 2014-06-30 Reduce -52.34%1.31%$51.23 - $54.54 $ 46.81-12%2602503
Bill Nygren 2014-06-30 Add 90.38%0.9%$51.23 - $54.54 $ 46.81-12%4950000
Scott Black 2014-06-30 Reduce -27.57%0.39%$51.23 - $54.54 $ 46.81-12%178985
John Hussman 2014-06-30 Sold Out 0.09%$51.23 - $54.54 $ 46.81-12%0
PRIMECAP Management 2014-06-30 Add 21.59%0.03%$51.23 - $54.54 $ 46.81-12%3011646
Scott Black 2014-03-31 New Buy1.4%$47.77 - $53.63 $ 46.81-8%247100
Bill Nygren 2014-03-31 New Buy1.1%$47.77 - $53.63 $ 46.81-8%2600000
HOTCHKIS & WILEY 2014-03-31 Add 65.83%0.75%$47.77 - $53.63 $ 46.81-8%9804594
James Barrow 2014-03-31 Add 22.72%0.39%$47.77 - $53.63 $ 46.81-8%27790116
NWQ Managers 2014-03-31 Reduce -6.39%0.17%$47.77 - $53.63 $ 46.81-8%5460055
HOTCHKIS & WILEY 2013-12-31 Add 23.53%0.27%$48.75 - $54 $ 46.81-9%5912375
Charles Brandes 2013-12-31 Add 18.29%0.2%$48.75 - $54 $ 46.81-9%2013300
NWQ Managers 2013-12-31 Add 7.52%0.19%$48.75 - $54 $ 46.81-9%5832760
Mario Gabelli 2013-12-31 Reduce -24.37%$48.75 - $54 $ 46.81-9%4500
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Sanofi

Bill Nygren Comments on Sanofi - Apr 08, 2014

Sanofi (SNY - $52)(SNY)
Sanofi is a pharmaceutical company with a good mix of durable businesses with strong growth characteristics. The company has a strong franchise in diabetes treatments, maintaining dominant market share in this rapidly growing category. Sanofi is a leading player in emerging markets, where sales growth rates are twice that of the overall pharmaceutical market. Sanofi is also a leader in vaccines, and they have a strong footprint in over-the-counter products. We think that margins and profitability should improve as the company leverages fixed R&D spending and enforces good cost controls. The company’s balance sheet has more cash than debt, and the shares sell at a substantial discount to our estimate of intrinsic value. Moreover, Sanofi has a dividend yield of 3.7%.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund first quarter 2014 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Sanofi

Top Held European Stocks Highlighted by Health Care and Oil and Gas Stocks
sing the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies were bought by the largest numbers of gurus over a certain period of time. By using this screener, we filtered down to see which companies based in Europe were held by the highest number of gurus. Read more...
Oakmark Funds' Bill Nygren Buys 4 New Stocks
Bill Nygren (Trades, Portfolio)’s Oakmark fund beat the S&P 500 for the first quarter with a 5% gain compared to the index’s 2% rise. In his first quarter letter, he attributed the strong quarter primarily to Forest Laboratories being acquired by Actavis Plc (ACT), and large exposure to auto-related cyclical and financials. Read more...
Bill Nygren Comments on Sanofi
Sanofi (SNY - $52)(SNY)
Sanofi is a pharmaceutical company with a good mix of durable businesses with strong growth characteristics. The company has a strong franchise in diabetes treatments, maintaining dominant market share in this rapidly growing category. Sanofi is a leading player in emerging markets, where sales growth rates are twice that of the overall pharmaceutical market. Sanofi is also a leader in vaccines, and they have a strong footprint in over-the-counter products. We think that margins and profitability should improve as the company leverages fixed R&D spending and enforces good cost controls. The company’s balance sheet has more cash than debt, and the shares sell at a substantial discount to our estimate of intrinsic value. Moreover, Sanofi has a dividend yield of 3.7%. Read more...
Top Held European Stocks Highlighted by Health Care and Oil and Gas Stocks
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies were bought by the largest numbers of gurus over a certain period of time. By using this screener, we filtered down to see which companies based in Europe were bought by the highest number of gurus. Read more...
Warren Buffett Shows Changes to International Stocks: Tesco, Munich Re, Sanofi, POSCO
Warren Buffett (Trades, Portfolio) reported the holding changes at Berkshire Hathaway (BRK.A)(BRK.B) last month, but he did not include his foreign stocks, as he is not required to by the SEC. Once a year, in his annual letters, however, he gives a glimpse of his international dealings by reporting the status of all his equity positions exceeding $1 billion in value. The latest letter, reported last week, revealed some notable changes in his international holdings. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 24.50
SNY's P/E(ttm) is ranked higher than
86% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.60 vs. SNY: 24.50 )
SNY' s 10-Year P/E(ttm) Range
Min: 9.64   Max: 38.97
Current: 24.5

9.64
38.97
P/S 3.02
SNY's P/S is ranked higher than
76% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.94 vs. SNY: 3.02 )
SNY' s 10-Year P/S Range
Min: 1.72   Max: 5.26
Current: 3.02

1.72
5.26
PFCF 13.55
SNY's PFCF is ranked higher than
96% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. SNY: 13.55 )
SNY' s 10-Year PFCF Range
Min: 5.11   Max: 45
Current: 13.55

5.11
45
EV-to-EBIT 16.92
SNY's EV-to-EBIT is ranked higher than
88% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.43 vs. SNY: 16.92 )
SNY' s 10-Year EV-to-EBIT Range
Min: 9.4   Max: 204.2
Current: 16.92

9.4
204.2
Shiller P/E 21.75
SNY's Shiller P/E is ranked higher than
91% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 160.36 vs. SNY: 21.75 )
SNY' s 10-Year Shiller P/E Range
Min: 11.39   Max: 25.36
Current: 21.75

11.39
25.36

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.08
SNY's Dividend Yield is ranked higher than
100% of the 519 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. SNY: 4.08 )
SNY' s 10-Year Dividend Yield Range
Min: 1.39   Max: 5.46
Current: 4.08

1.39
5.46
Dividend Payout 0.90
SNY's Dividend Payout is ranked higher than
68% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. SNY: 0.90 )
SNY' s 10-Year Dividend Payout Range
Min: 1.17   Max: 8.15
Current: 0.9

1.17
8.15
Dividend growth (3y) 4.90
SNY's Dividend growth (3y) is ranked higher than
81% of the 380 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. SNY: 4.90 )
SNY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 22.1
Current: 4.9

0
22.1
Yield on cost (5-Year) 5.44
SNY's Yield on cost (5-Year) is ranked higher than
93% of the 528 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.47 vs. SNY: 5.44 )
SNY' s 10-Year Yield on cost (5-Year) Range
Min: 1.84   Max: 7.24
Current: 5.44

1.84
7.24
Share Buyback Rate -0.80
SNY's Share Buyback Rate is ranked higher than
78% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.30 vs. SNY: -0.80 )
SNY' s 10-Year Share Buyback Rate Range
Min: 1.3   Max: -24.6
Current: -0.8

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.08
SNY's Price/DCF (Projected) is ranked higher than
95% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. SNY: 1.08 )
SNY' s 10-Year Price/DCF (Projected) Range
Min: 0.48   Max: 5.65
Current: 1.08

0.48
5.65
Price/Median PS Value 1.06
SNY's Price/Median PS Value is ranked higher than
82% of the 947 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.29 vs. SNY: 1.06 )
SNY' s 10-Year Price/Median PS Value Range
Min: 0.63   Max: 8.62
Current: 1.06

0.63
8.62
Earnings Yield (Greenblatt) 5.90
SNY's Earnings Yield (Greenblatt) is ranked higher than
87% of the 906 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. SNY: 5.90 )
SNY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 10.6
Current: 5.9

0.5
10.6
Forward Rate of Return (Yacktman) 3.26
SNY's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 496 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.85 vs. SNY: 3.26 )
SNY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.9   Max: 60.3
Current: 3.26

1.9
60.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:0O59.UK, SAN.France, SANF.Italy, SNW2.Germany, SNW.Germany, SNYNF.USA, SNYN.Mexico, SAN.Switzerland,
Sanofi was incorporated under the laws of France in 1994 as a société anonyme, a form of limited liability company. It is a healthcare company, engaged in the research, development, manufacture and marketing of healthcare products. Its principal activities include Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. It also operates through the following platforms: Emerging Markets, Diabetes Solutions, Vaccines, Consumer Health Care (CHC), Animal Health, Genzyme, and Other Innovative Products. The Pharmaceuticals segment covers research, development, production and marketing of medicines, including activities acquired with Genzyme. Sanofi's pharmaceuticals portfolio consists of flagship products, plus prescription medicines, generic medicines, and consumer health products. This segment also includes all associates and joint ventures whose activities are related to pharmaceuticals, in particular the entities majority owned by BMS. The Vaccines segment is wholly dedicated to vaccines, including research, development, production and marketing. This segment includes Sanofi Pasteur MSD joint venture with Merck & Co., Inc. in Europe. The Animal Health segment comprises the research, development, production and marketing activities of Merial, which offers medicines and vaccines for a wide variety of animal species. Its competitors include Novo Nordisk, Merck, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Shire, Pfizer, Biogen Idec, Teva and Merck Serono, Bayer, Roche, Johnson & Johnson, AstraZeneca, Boehringer-Ingelheim, Fresenius Medical Care, among others. The Company's products and manufacturing facilities are subject to significant government regulations and approvals.
» More Articles for SNY

Headlines

Articles On GuruFocus.com
The Top 5 European Stocks Held During Q3 Nov 25 2014 
Guru Stocks at 52-Week Lows: IBM, SNY, SAN, RIO, E Nov 09 2014 
Guru Stocks at 52-Week Lows: IBM, BBL, SNY, SAN, RIO Nov 04 2014 
Zoetis Will Benefit from Industry Trends Oct 07 2014 
International Securities For A Diversified Income Portfolio Sep 23 2014 
Widely Held Guru Stocks Trading In Europe Sep 22 2014 
Why Investing Internationally Can Help Your Portfolio Sep 12 2014 
The MS Global Franchise Fund's Top Five Stocks Sep 10 2014 
Guru Stocks at 52-Week Lows: CHL, TM, SNY, NVO, TSM Sep 02 2014 
Sarah Ketterer’s Causeway International Value Fund Reports Top Five Aug 31 2014 

More From Our Partners
Alnylam Provides Pipeline Update, Growth Strategy - Analyst Blog Dec 15 2014 - ZACKS

More From Other Websites
5 Big Stocks to Trade After the Fed's Rate News: Microsoft, Goldman and More Dec 18 2014
Merial acquires two major equine health products from Bayer Dec 17 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Dec 16 2014
Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations... Dec 15 2014
Sanofi Pasteur Announces FDA Approval of Fluzone® Intradermal Quadrivalent (Influenza Vaccine) for... Dec 12 2014
The Big Business of Selling Prescription-Drug Records Dec 11 2014
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Sanofi SA and... Dec 11 2014
Livestock products lead Zoetis’ 3Q14 revenue growth Dec 11 2014
Robbins Arroyo LLP: Sanofi (SNY) Misled Shareholders According to a Recently Filed Class Action Dec 10 2014
Must-know trends that drive Zoetis’ growth Dec 10 2014
Toast The New Year With 5 Undervalued Dividend Stocks Dec 10 2014
Will Sanofi (SNY) Stock Advance Today on Diversification, Acquisitions Strategy? Dec 10 2014
Pershing Square takes 8.5% stake in Zoetis Dec 10 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From... Dec 09 2014
Zoetis Inc. Spikes Briefly On Remarks From Sanofi CEO Dec 09 2014
ImmunoGen Reports Encouraging Data on Cancer Drug Dec 08 2014
Merck Acquiring Cubist, Focusing On Hospital Care Dec 08 2014
Law Offices of Marc S. Henzel Announces Securities Class Action Periods Dec 08 2014
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible... Dec 08 2014
SANOFI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds... Dec 05 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK